BRAF mutation in thyroid cancer

Endocrine-Related Cancer

Volumn 12, Issue 2, 2005, Pages 245-262

  Xing, M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; DNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; THYROTROPIN RECEPTOR;

ASPIRATION BIOPSY; BRAF GENE; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER RISK; DIAGNOSTIC VALUE; GENE; GENE MUTATION; GENE REARRANGEMENT; HISTOLOGY; HUMAN; PREVALENCE; PROGNOSIS; RADIATION EXPOSURE; REVIEW; RISK ASSESSMENT; THYROID CANCER; THYROID PAPILLARY CARCINOMA;

AGE FACTORS; GENE REARRANGEMENT; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; ONCOGENE PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 21244457181     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.0978     Document Type: Review

References (133)

1. Abravaya K, Carrino JJ, Muldoon S & Lee HH 1995 Detection of point mutations with a modified ligase chain reaction (Gap-LCR). Nucleic Acids Research 23 675-682.
2. Akslen LA & LiVolsi VA 2000 Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer 88 1902-1908.
3. Al-Shaikh A, Ngan B, Daneman A & Daneman D 2001 Fine-needle aspiration biopsy in the management of thyroid nodules in children and adolescents. Journal of Pediatrics 138 140-142.
4. Avvedimento VE, Musti AM, Ueffing M, Obici S, Gallo A, Sanchez M, DeBrasi D & Gottesman ME 1991 Reversible inhibition of a thyroid-specific transacting factor by Ras. Genes and Development 5 22-28.
5. Baloch Z, Kumar MS, Lai M, Volpe P, LiVolsi VA, Mandel SJ & Brose MS 2004 Rate of BRAF and N-Ras mutations in thyroid nodules undergoing fine needle aspiration. Thyroid 14 745.
6. Basolo F, Giannini R, Monaco C, Melillo RM, Carlomagno F, Pancrazi M, Salvatore G, Chiappetta G, Pacini F, Elisei R et al. 2002 Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. American Journal of Pathology 160 247-254.
7. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D & Westra WH 2004 BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Modern Pathology 17 1359-1363.
8. Belfiore A, Giuffrida D, La Rosa GL, Ippolito O, Russo G, Fiumara A, Vigneri R & Filetti S 1989 High frequency of cancer in cold thyroid nodules occurring at young age. Acta Endocrinologica (Copenhagen) 121 197-202.
9. Berlingieri MT, Akamizu T, Fusco A, Grieco M, Colletta G, Cirafici AM, Ikuyama S, Kohn LD & Vecchio G 1990 Thyrotropin receptor gene expression in oncogene-transfected rat thyroid cells: correlation between transformation, loss of thyrotropin-dependent growth, and loss of thyrotropin receptor gene expression. Biochemical and Biophysical Research Communications 173 172-178.
10. Bollag G, Freeman S, Lyons JF & Post LE 2003 Raf pathway inhibitors in oncology. Current Opinion in Investigative Drugs 4 1436-1441.
11. Bongarzone I & Pierotti MA 2003 The molecular basis of thyroid epithelial tumorigenesis. Tumori 89 514-516.
12. Bounacer A, Wicker R, Caillou B, Cailleux AF, Sarasin A, Schlumberger M & Suarez HG 1997 High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 15 1263-1273.
13. Brander A, Viikinkoski P, Nickels J & Kivisaari L 1991 Thyroid gland: US screening in a random adult population. Radiology 181 683-687.
14. Bruneton JN, Balu-Maestro C, Marcy PY, Melia P & Mourou MY 1994 Very high frequency (13MHz) ultrasonographic examination of the normal neck: detection of normal lymph nodes and thyroid nodules. Journal of Ultrasound in Medicine 13 87-90.
15. Bunone G, Uggeri M, Mondellini P, Pierotti MA & Bongarzone I 2000 RET receptor expression in thyroid follicular epithelial cell-derived tumors. Cancer Research 60 2845-2849.
16. Castro MR & Gharib H 2000 Thyroid nodules and cancer. When to wait and watch, when to refer. Postgraduate Medicine 107 113-116, 119-120, 123-124.
17. Chan JK 1990 Papillary carcinoma of thyroid: classical and variants. Histology and Histopathology 5 241-257.
18. Cheng G & Meinkoth JL 2001 Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells. Oncogene 20 7334-7341.
19. Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, Wentworth J, Philips J, Clifton-Bligh R & Robinson BG 2003 Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. Journal of Clinical Endocrinology and Metabolism 88 354-357.
20. Chow SM, Law SC, Chan JK, Au SK, Yau S & Lau WH 2003 Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer 98 31-40.
21. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA & Nikiforov YE 2005 Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. Journal of Clinical Investigation 115 94-101.
22. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW & Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. Journal of National Cancer Institute 95 625-627.
23. Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D & Westra WH 2004 Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clinical Cancer Research 10 2761-2765.
24. Conard RA, Dobyns BM & Sutow WW 1970 Thyroid neoplasia as late effect of exposure to radioactive iodine in fallout. Journal of the American Medical Association 214 316-324.
25. Dammann R, Li C, Yoon JH, Chin PL, Bates S & Pfeifer GP 2000 Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nature Genetics 25 315-319.
26. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al. 2002 Mutations of the BRAF gene in human cancer. Nature 417 949-954.
27. Dhillon AS & Kolch W 2004 Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell 5 303-304.
28. Duffy BJ Jr & Fitzgerald PJ 1950 Cancer of the thyroid in children: a report of 28 cases. Journal of Clinical Endocrinology and Metabolism 10 1296-1308.
29. Dumas J, Smith RA & Lowinger TB 2004 Recent developments in the discovery of protein kinase inhibitors from the urea class. Current Opinion in Drug Discovery and Development 7 600-616.
30. Elisei R, Romei C, Vorontsova T, Cosci B, Veremeychik V, Kuchinskaya E, Basolo F, Demidchik EP, Miccoli P, Pinchera A et al. 2001 RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. Journal of Clinical Endocrinology and Metabolism 86 3211-3216.
31. Fagin JA 2002 Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Molecular Endocrinology 16 903-911.
32. Fagin JA 2004 Challenging dogma in thyroid cancer molecular genetics-role of RET/PTC and BRAF in tumor initiation. Journal of Clinical Endocrinology and Metabolism 89 4264-4266.
33. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL & Tuttle RM 2000 The RET/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. Journal of Clinical Endocrinology and Metabolism 85 1170-1175.
34. Franc B 2003 Observer variation of lesions of the thyroid. American Journal of Surgical Pathology 27 1177-1179.
35. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S et al. 2004 Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23 7436-7740.
36. Fugazzola L, Pilotti S, Pinchera A, Vorontsova TV, Mondellini P, Bongarzone I, Greco A, Astakhova L, Butti MG, Demidchik EP et al. 1995 Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Research 55 5617-5620.
37. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L & Beck-Peccoz P 2004 BRAF mutations in an Italian cohort of thyroid cancers. Clinical Endocrinology (Oxford) 61 239-243.
38. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K & Takenoshita S 2003 BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22 6455-6457.
39. Fusco A, Viglietto G & Santoro M 2005 A new mechanism of BRAF activation in human thyroid papillary carcinomas. Journal of Clinical Investigation 115 20-23.
40. Garnett MJ & Marais R 2004 Guilty as charged: BRAF is a human oncogene. Cancer Cell 6 313-319.
41. Gharib H, Goellner JR, Zinsmeister AR, Grant CS & Van Heerden JA 1984 Fine-needle aspiration biopsy of the thyroid. The problem of suspicious cytologic findings, Annals of Internal Medicine 101 25-28.
42. Gire V, Marshall C & Wynford-Thomas D 2000 PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene 19 2269-2276.
43. Goldenberg D, Rosenbaum E, Argani P, Wistuba II, Sidransky D, Thuluvath PJ, Hidalgo M, Califano J & Maitra A 2004 The V599E BRAF mutation is uncommon in biliary tract cancers. Modern Pathology 17 1386-1391.
44. Greaves TS, Olvera M, Florentine BD, Raza AS, Cobb CJ, Tsao-Wei DD, Groshen S, Singer P, Lopresti J & Martin SE 2000 Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer 90 335-341.
45. Hayashida N, Namba H, Kumagai A, Hayashi T, Ohtsuru A, Ito M, Saenko VA, Maeda S, Kanematsu T & Yamashita S 2004 A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid 14 910-915.
46. Hegedus L 2004 Clinical practice. The thyroid nodule. New England Journal of Medicine 351 1764-1771.
47. Hilger RA, Scheulen ME & Strumberg D 2002 The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25 511-518.
48. Hubbard SR 2004 Oncogenic mutations in B-Raf: some losses yield gains. Cell 116 764-766.
49. Hundahl SA, Fleming ID, Fremgen AM & Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83 2638-2648.
50. Ichihara M, Murakumo Y & Takahashi M 2004 RET and neuroendocrine tumors. Cancer Letters 204 197-211.
51. Ito T, Seyama T, Iwamoto KS, Hayashi T, Mizuno T, Tsuyama N, Dohi K, Nakamura N & Akiyama M 1993 In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Research 53 2940-2943.
52. Ito T, Seyama T, Iwamoto KS, Mizuno T, Tronko ND, Komissarenko IV, Cherstovoy ED, Satow Y, Takeichi N, Dohi K et al. 1994 Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet 344 259.
53. Jarry A, Masson D, Cassagnau E, Parois S, Laboisse C & Denis MG 2004 Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Molecular and Cellular Probes 18 349-352.
54. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY, Xing S & Ledent C 1996 Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137 375-378.
55. Jhiang SM, Cho JY, Furminger TL, Sagartz JE, Tong Q, Capen CC & Mazzaferri EL 1998 Thyroid carcinomas in RET/PTC transgenic mice. Recent Results. Cancer Research 154 265-270.
56. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Medley D, Martin J, Marshall CJ et al. 2004 B-RAF is a therapeutic target in melanoma. Oncogene 23 6292-6298.
57. Kazakov VS, Demidchik EP & Astakhova LN 1992 Thyroid cancer after Chernobyl. Nature 359 21.
58. Kim DW, Hwang JH, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM et al. 2003 RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1. Molecular Endocrinology 17 1382-1394.
59. Kim KH, Kang DW, Kim SH, Seong IO & Kang DY 2004 Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Medical Journal 45 818-821.
60. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 63 1454-1457.
61. Kimura ET, Vanvooren V, van Sande J, Nikiforov YE & Fagin JA 2004 Autonomously functioning thyroid nodules are not associated with BRAF mutations. Clinical Endocrinology (Oxford) 60 394-396.
62. Klugbauer S, Lengfelder E, Demidchik EP & Rabes HM 1995 High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 11 2459-2467.
63. Knauf JA, Kuroda H, Basu S & Fagin JA 2003 RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 11 4406-4412.
64. V600E in thryoid cells of transgenic mice results in papillary thyroid cancers that transition to undifferentiated carcinomas. The 76th American Thyroid Association Annual Meeting, Vancouver, British Columbia, Canada. Abstract, short-call program #2.
65. Koper JW & Lamberts SW 2000 Sporadic endocrine tumours and their relationship to the hereditary endocrine neoplasia syndromes. European Journal of Clinical Investigation 30 493-500.
66. Krohn K & Paschke R 2004 BRAF mutations are not an alternative explanation for the molecular etiology of ras-mutation negative cold thyroid nodules. Thyroid 14 359-361.
67. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM & Fletcher JA 2000 PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 289 1357-1360.
68. Kumagai A, Namba H, Saenko VA, Ashizawa K, Ohtsuru A, Ito M, Ishikawa N, Sugino K, Ito K, Jeremiah S et al. 2004 Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. Journal of Clinical Endocrinology Metabolism 89 4280-4284.
69. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S & Hemminki K 2003 BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clinical Cancer Research 9 3362-3368.
70. Kumar MS, Moore KE & Brose MS 2004 Functional analysis of BRAF in a papillary thyroid cancer cell line. Thyroid 14 712.
71. Lee JT & McCubrey JA 2003 BAY-43-9006. Bayer/Onyx. Current Opinion in Investigative Drugs 4 757-763.
72. Lilleberg SL, Durocher J, Sanders C, Walters K & Culver K 2004 High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. Annals of the New York Academy of Sciences 1022 250-256.
73. Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A et al. 2004 BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 89 4267-4271.
74. Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K et al. 2004 Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. American Journal of Surgical Pathology 28 1336-1340.
75. McIver B, Grebe SK & Eberhardt NL 2004 The PAX8/PPARgamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Current Drug Targets. Immune, Endocrine and Metabolic Disorders 4 221-234.
76. Mercer KE & Pritchard CA 2003 Raf proteins and cancer: B-Raf is identified as a mutational target. Biochimica et Biophysica Acta 1653 25-40.
77. Merino MJ & Monteagudo C 1997 Tall cell carcinoma of the thryoid: an aggressive variant of papillary cancer. Pathology Case Reviews 2 196-199.
78. Miyagi E, Braga-Basaria M, Hardy E, Vasko V, Burman K, D, Jhiang S, Saji M & Ringel MD 2004 Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Molecular Carcinogenesis 41 98-107.
79. Mizuno T, Kyoizumi S, Suzuki T, Iwamoto KS & Seyama T 1997 Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 15 1455-1460.
80. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T & Yamashita S 2003 Clinical Implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 88 4393-4397.
81. Nikiforov YE 2002 RET/PTC rearrangement in thyroid tumors. Endocrine Pathology 13 3-16.
82. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H & Fagin JA 1997 Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Research 57 1690-1694.
83. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 88 5399-5404.
84. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD et al. 2004 Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters 209 1-6.
85. Nilsson M 2001 Iodide handling by the thyroid epithelial cell. Experimental & Clinical Endocrinology and Diabetes 109 13-17.
86. Omholt K, Platz A, Kanter L, Ringborg U & Hansson J 2003 NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clinical Cancer Research 9 6483-6488.
87. Penko KS, Livezey J, Fenton CL, Patel A, Nicholson D, Flores M, Oakley K, Tuttle RM & Francis GL 2004 BRAF mutations are less common in childhood papillary thyroid cancer (PTC) than adult PTC. Thyroid 14 750.
88. Perren A, Schmid S, Locher T, Saremaslani P, Bonvin C, Heitz PU & Komminoth P 2004 BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocrine-Related Cancer 11 855-860.
89. Peyssonnaux C & Eychene A 2001 The Raf/MEK/ERK pathway: new concepts of activation. Biology of the Cell 93 53-62.
90. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP & Dammann R 2002 Methylation of the RASSF1A gene in human cancers. Biological Chemistry 383 907-914.
91. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hosteller G, Wagner U, Kakareka J et al. 2003 High frequency of BRAF mutations in nevi. Nature Genetics 33 19-20.
92. Powell DJ Jr, Russell J, Nibu K, Li G, Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A et al. 1998 The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Research 58 5523-5528.
93. Prendiville S, Burman KD, Ringel MD, Shmookler BM, Deeb ZE, Wolfe K, Azumi N, Wartofsky L & Sessions RB 2000 Tall cell variant: an aggressive form of papillary thyroid carcinoma. Otolaryngotogy Head and Neck Surgery 122 352-357.
94. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G et al. 2004 BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 89 2414-2420.
95. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B & Velculescu VE 2002 Tumorigenesis: RAF/RAS oncogenes and mismatch-repair slalus. Nature 418 934.
96. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP et al. 2004 Multicenter phase II study of the oral MEK inhibitor, C1-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. Journal of Clinical Oncology 22 4456-4462.
97. Rosenberg AM, Cradic KW, Sekulic A, Mai M, Pittelkow MR, Halling KC, Erickson LA, Hay ID, Eberhardt NL, Mclver B et al. 2004 Detection of circulating BRAF-mutant cell in papillary thyroid carcinoma. The Endocrine Society's 86th Annual Meeting, New Orleans, LA, USA. Abstract OR21-6.
98. Sahin M, Allard BL, Yates M, Powell JG, Wang XL, Hay ID, Zhao Y, Goellner JR, Sebo TJ, Grebe SK et al. 2005 PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinico-pathologic correlation and histopathological diagnostic value. Journal of Clinical Endocrinology and Metabolism 90 463-468.
99. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F et al. 2004 Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 89 5175-5180.
100. Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, Manzo G, Picone A, Portella G, Santelli G, Vecchio G et al. 1996 Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12 1821-1826.
101. Santoro M, Melillo RM, Carlomagno F, Fusco A & Vecchio G 2002 Molecular mechanisms of RET activation in human cancer. Annals of the New York Academy of Sciences 963 116-121.
102. Santoro M, Melillo RM, Carlomagno F, Vecchio G & Fusco A 2004 Minireview: RET: normal and abnormal functions. Endocrinology 145 5448-5451.
103. Schagdarsurengin LJ, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP & Dammann R 2002 Frequent epigenetic silencing of the CpG island promoter of RASSFIA in thyroid carcinoma. Cancer Research 62 3698-3701.
104. Sclabas GM, Staerkel GA, Shapiro SE, Fornage BD, Sherman SI, Vassillopoulou-Sellin R, Lee JE & Evans DB 2003 Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. American Journal of Surgery 186 702-709.
105. Sebolt-Leopold JS 2004 MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Current Pharmaceutical Design 10 1907-1914.
106. Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, Abrosimov A, Lushnikov E, Kumagai A, Nakashima M, Meirmanov S et al. 2004 The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. International Journal of Oncology 25 1729-1735.
107. Sherman SI 2003 Thyroid carcinoma. Lancet 361 501-511.
108. Shore RE, Woodard E, Hildreth N, Dvoretsky P, Hempelmann L & Pasternack B 1985 Thyroid tumors following thymus irradiation. Journal of National Cancer Institute 74 1177-1184.
109. Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ & Shih IeM 2003 Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Journal of National Cancer Institute 95 484-486.
110. Sithanandam G, Druck T, Cannizzaro LA, Leuzzi G, Huebner K & Rapp UR 1992 B-raf and a B-raf pseudogene are located on 7q in man. Oncogene 1 795-799.
111. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R & Sobrinho-Simoes M 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22 4578-4580.
112. Soares P, Trovisco V, Rocha AS, Feijao T, Rebocho AP, Fonseca E, Vieira de Castro I, Cameselle-Teijeiro J, Cardoso-Oliveira M & Sobrinho-Simoes M 2004 BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Archiv 444 572-576.
113. Tallini G 2002 Molecular pathobiology of thyroid neoplasms. Endocrine Pathology 13 271-288.
114. Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM & Sobrinho-Simoes M 2004 BRAF mutations are associated with some histological types of papillary thyroid carcinoma. Journal of Pathology 202 247-251.
115. Unger K, Zitzelsberger H, Salvatore G, Santoro M, Bogdanova T, Braselmann H, Kastner P, Zurnadzhy L, Tronko N, Hutzler P et al. 2004 Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 89 4272-4279.
116. Vander JB, Gaston EA & Dawber TR 1968 The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Annals of Internal Medicine 69 537-540.
117. Vasil'ev EV, Roumiantsev PO, Saenko VA, Il'in AA, Polyakova EY, Nemtsova MV & Zaletayev DV 2004 Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene. Molecular Biology (Moscow) 38 642-653.
118. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF & de Micco C 2003 Specific pattern of RAS oncogene mutations in follicular thyroid tumors. Journal of Clinical Endocrinology and Metabolism 88 2745-2752.
119. Vdovichenko KK, Markova SI & Belokhvostov AS 2004 Mutant form of BRAF gene in blood plasma of cancer patients. Annals of the New York Academy of Sciences 1022 228-231.
120. Venkataraman GM, Yatin M, Marcinek R & Ain KB 1999 Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. Journal of Clinical Endocrinology and Metabolism 84 2449-2457.
121. Vos MD, Ellis CA, Bell A, Birrer MJ & Clark GJ 2000 Ras uses the novel tumor suppressor RASSFI as an effector to mediate apoptosis. Journal of Biological Chemistry 275 35669-35672.
122. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D et al. 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 855-867.
123. Werk EE Jr, Vernon BM, Gonzalez JJ, Ungaro PC & McCoy RC 1984 Cancer in thyroid nodules. A community hospital survey. Archives of Internal Medicine 144 474-476.
124. Wilhelm S & Chien DS 2002 BAY 43-9006 colon; preclinical data. Current Pharmaceutical Design 8 2255-2257.
125. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64 7099-7109.
126. Wood JW, Tamagaki H, Neriishi S, Sato T, Sheldon WF, Archer PG, Hamilton HB & Johnson KG 1969 Thyroid carcinoma in atomic bomb survivors Hiroshima and Nagasaki. American Journal of Epidemiology 89 4-14.
127. Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, Tong BC, Tallini G, Udelsman R, Califano JA et al. 2003a Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Research 63 2316-2321.
128. Xing M, Tokumaru Y, Wu G, Westra WB, Ladenson PW & Sidransky D 2003b Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis. Cancer Research 63 2312-2315.
129. Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW & Sidransky D 2004a Early occurrence of RASSFIA hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Research 64 1664-1668.
130. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW & Sidransky D 2004b BRAF T1796A transversion mutation in various thyroid neoplasms. Journal of Clinical Endocrinology and Metabolism 89 1365-1368.
131. Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D & Ladenson PW 2004c Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 89 2867-2872.
132. Xu X, Quiros RM, Gattuso P, Ain KB & Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Research 63 4561-4567.
133. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH & Nikiforov YE 2003 Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. American Journal of Clinical Pathology 120 71-77.